Literature DB >> 10986307

Prediction of disease progression in early rheumatoid arthritis by ICTP, RF and CRP. A comparative 3-year follow-up study.

S Aman1, L Paimela, M Leirisalo-Repo, J Risteli, H Kautiainen, T Helve, M Hakala.   

Abstract

OBJECTIVE: To test the predictive value of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP; a marker of type I collagen degradation), rheumatoid factor (RF) and C-reactive protein (CRP) for disease progression in patients with early rheumatoid arthritis (RA)
METHOD: We tested the value of baseline values of RF, CRP and ICTP for the prediction of radiological joint progression over 3 yr in 63 consecutive patients with early RA who were treated with the 'saw-tooth strategy'.
RESULTS: Age- and sex-adjusted risks as odds ratios (95% confidence intervals) of elevated serum ICTP, RF positivity and increased CRP for progressive joint disease (defined as an increase of > 20 in Larsen's index on radiographs of the hands and feet) were 3.9 (1.3, 11.9), 3.9 (1.0, 15.5) and 2.6 (0.9, 7.5), respectively. Better prediction was achieved when the tests were used in combination, and where there was both elevated ICTP and positive RF the odds ratio was 9.1 (2.5, 32.9). This test combination showed good sensitivity and specificity (71 and 77%, respectively), with a positive predictive value of 65% and a likelihood ratio of 3.1.
CONCLUSION: This kind of risk profile, in which the tests used reflect different aspects of the disease process, may be useful in early disease assessment to find patients who will need the most active drug therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10986307     DOI: 10.1093/rheumatology/39.9.1009

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  9 in total

Review 1.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

2.  Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction.

Authors:  Kosuke Ebina; Atsunori Fukuhara; Wataru Ando; Makoto Hirao; Tadashi Koga; Kazuya Oshima; Morihiro Matsuda; Kazuhisa Maeda; Tadashi Nakamura; Takahiro Ochi; Iichiro Shimomura; Hideki Yoshikawa; Jun Hashimoto
Journal:  Clin Rheumatol       Date:  2008-12-16       Impact factor: 2.980

3.  C-reactive protein and fibrinogen of bedridden older patients in a six-month vitamin D supplementation trial.

Authors:  M P Bjorkman; A J Sorva; R S Tilvis
Journal:  J Nutr Health Aging       Date:  2009-05       Impact factor: 4.075

4.  Serum C-reactive protein in dairy herds.

Authors:  Wen-Chuan Lee; Huo-Cheng Hsiao; Ying-Ling Wu; Jyh-Hung Lin; Yen-Pai Lee; Hang-Poung Fung; Hsin-Hsin Chen; Yu-Hsin Chen; Rea-Min Chu
Journal:  Can J Vet Res       Date:  2003-05       Impact factor: 1.310

5.  Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis.

Authors:  Marianna M Newkirk; Raphaela Goldbach-Mansky; Jennifer Lee; Joseph Hoxworth; Angie McCoy; Cheryl Yarboro; John Klippel; Hani S El-Gabalawy
Journal:  Arthritis Res Ther       Date:  2003-01-06       Impact factor: 5.156

6.  Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year.

Authors:  Jonathan Kay; Olga Morgacheva; Susan P Messing; Joel M Kremer; Jeffrey D Greenberg; George W Reed; Ellen M Gravallese; Daniel E Furst
Journal:  Arthritis Res Ther       Date:  2014-02-03       Impact factor: 5.156

7.  Chromatin accessibility landscapes of immune cells in rheumatoid arthritis nominate monocytes in disease pathogenesis.

Authors:  Dandan Zong; Beibei Huang; Young Li; Yichen Lu; Nan Xiang; Chuang Guo; Qian Liu; Qing Sha; Pengcheng Du; Qiaoni Yu; Wen Zhang; Pengfei Cai; Yanping Sun; Jinhui Tao; Xiaomei Li; Shanbao Cai; Kun Qu
Journal:  BMC Biol       Date:  2021-04-16       Impact factor: 7.431

Review 8.  Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis.

Authors:  Paul Emery; Cem Gabay; Maarten Kraan; Juan Gomez-Reino
Journal:  Rheumatol Int       Date:  2007-05-16       Impact factor: 3.580

9.  Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy.

Authors:  Johann Schoenberger; Silke Rozeboom; Eva Wirthgen-Beyer; Christoph Eilles
Journal:  BMC Nucl Med       Date:  2004-12-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.